The deregulation of translation markedly contributes to the malignant phenotype in cancers and the assembly of the translation initiating complex eIF4F is the limiting step of this process. The mammalian Target Of Rapamycin Complex 1 (mTORC1) is thought to positively regulate eIF4F assembly and subsequent oncogenic protein synthesis through 4E-BP1 phosphorylation. We showed here that the translation inhibitor 4EGI-1 decreased the clonogenic growth of leukemic progenitors and induced apoptosis of blast cells, with limited toxicity against normal hematopoiesis, which emphasize the importance of translation deregulation in AML biology. However, the mTORC1 inhibitor RAD001 (a rapamycin derivate) did not induce AML blast cell apoptosis. We herein demonstrated that mTORC1 disruption using raptor siRNA or RAD001 failed to inhibit 4E-BP1 phosphorylation in AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a clonal hematological disease characterized by differentiation arrest and by the proliferation of immature myeloid progenitors, both sustained by the deregulation of multiple signaling pathways 1 . Despite recent advances in the understanding of AML biology, the prognosis of this disease remains poor and new therapeutic perspectives are therefore under active investigation 2 .
In most cancer models, the activity of mammalian Target Of Rapamycin Complex 1 (mTORC1) is dependent upon the activation of Akt, an oncoprotein which operates downstream of class IA Phosphoinositide 3 Kinase (PI3K) 3 . In AML, mTORC1 is frequently activated 4 but recent evidence has suggested that this activity does not rely on PI3K/Akt.
These findings have shown that the p110δ isoform of PI3K is principally responsible for PI3K activity 5 and that a specific p110δ inhibitor, IC87114, fully inhibits Akt phosphorylation without affecting mTORC1 activity 6 . Moreover, the Src kinase Lyn has recently been shown to control mTORC1 activity but not Akt phosphorylation in primary AML cells 7 .
The mTORC1 complex consists of mTOR, raptor, mLST8 and PRAS40 8 . It governs cell growth and regulates the cap-dependent translation of mRNAs 9 . Rapamycin and derivates, referred as rapalogs (e.g. RAD001), are closely related molecules demonstrating similar biological activities by specifically repressing mTORC1 activity 10, 11 . These compounds have recently been developed as anti-cancer therapeutics, due to the frequent activation of mTORC1 in cancers and approved for clinical use 12 . Despite their seemingly clear mechanism of action and the rationale for their use as a cancer therapeutic, rapalogs have had only modest successes in clinical trials 3 . In the case of AML, mTORC1 is frequently activated and rapamycin reduces the clonogenic growth of AML cells and sensitize blast cells to chemotherapy-induced cell death 4 . However, rapamycin barely induces apoptosis and only
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Different mechanisms of resistance to rapamycin have been described in human cancer cell lines 14 . In primary AML cells, mTORC1 inhibition using RAD001 increases PI3K/Akt activity via an IGF-1/IGF-1R autocrine loop 6 . However, this mechanism provides only a partial explanation of resistance to rapamycin as the dual inhibition of mTORC1 using RAD001 and PI3K using IC87114 reduces AML blast cell proliferation but does not induce apoptosis 6, 13, 15 .
As the mTORC1 pathway is known to stimulate protein synthesis, the moderate antileukemic activity of rapamycin led us to investigate the importance of translation in AML biology. In eukaryotic cells, translation is tightly regulated at the initiation level and is controlled by the mTORC1 pathway. The serine/threonine kinase activity of mTORC1 is dependent upon raptor, which positively regulates mTOR by acting as a scaffold for mTORC1 substrates, the ribosomal protein S6 Kinase (S6K) and the eukaryotic initiation factor 4E (eIF4E)-Binding Proteins (4E-BPs) 3, 16, 17 . The 4E-BPs are necessary for the control of translation initiation downstream of mTORC1 and although three isoforms exist in mammals, most studies have focused on 4E-BP1. The eIF4E protein recognizes the 7-methyl-GTP ( 7 m-GTP) cap structure at the 5' end of mRNA molecules 18 and associates with the scaffold protein eIF4G to form the eIF4F translation initiation complex. 4E-BP1 inhibits the formation of eIF4F by competitively inhibiting the recruitment of eIF4G and sequestering eIF4E in an inactive complex. 4E-BP1 can be sequentially phosphorylated on multiple residues. Primary phosphorylations on T 37 and T 46 residues are dependent of mTOR although they do not require raptor and are somewhat insensitive to rapamycin 19, 20 . They are necessary for subsequent phosphorylation on T 70 and then on S 65 that are critical for the release of 4E-BP1 from eIF4E 21, 22, 23 .
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In contrast to the observations made in AML, this model predicts a high degree of anti-tumor activity using mTORC1 inhibitors. Indeed, mechanisms implicated in protein synthesis strongly contribute to malignancy. A direct deregulation of translation initiation by eIF4E overexpression or by constitutive 4E-BP1 phosphorylation is commonly found in cancers and contributes to the oncogenic process through a sustained translation of malignancy-related transcripts, such as c-Myc and Cyclin D1 24 . Indeed, mRNAs are translated with varying efficiencies depending on the structure of their 5'untranslated region (UTR). The short unstructured 5'ends of mRNAs encoded by housekeeping genes (i.e. "strong" mRNAs:
actin) enable efficient translation under basal conditions. Conversely, the long structured 5'UTR of mRNA molecules encoded by oncogenes ("weak" mRNAs: c-Myc, Cyclin D1, and Bcl-xL) require an increased availability of eIF4F to achieve efficient translation 18, 25, 26 .
We show herein that targeting translation demonstrated a marked anti-leukemic potential in AML. In primary AML cells, specific inhibition of cap-dependent translation was achieved using a 4E-BP1 mimetic, the small molecule 4EGI-1 27 . This compound dramatically decreased the clonogenic growth of AML precursors, and induced massive blast cell apoptosis, with minimal impairment of normal hematopoiesis ex vivo. However, mRNA translation escapes mTORC1 control in primary AML cells. The phosphorylation of P70S6K on T 389 , a typical downstream relay of mTORC1, was abrogated by RAD001 or raptor siRNA whereas the phosphorylation of 4E-BP1 on S 65 residue, essential for the control of translation initiation, was unaffected. Therefore, RAD001 failed to inhibit mRNA translation: unlike 4EGI-1, RAD001 did not inhibit the assembly of eIF4F complexes and did not reduce the association of c-Myc mRNA with polysomes. We identified the Pim-2 serine/threonine kinase, acting in a raptor-independent and rapamycin-insensitive way, as mainly responsible for 4E-BP1 phosphorylation on S 65 and subsequent cap-dependent translation control in AML. Indeed, pim-2 knock-down and treatment of AML cells by 4EGI-1 strongly reduced
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Our results implicate a rapamycin-insensitive deregulation of oncogenic proteins expression in human myeloid leukemogenesis and strongly support the development of therapeutic strategies that directly target the eIF4F translation initiating complex in AML.
MATERIALS AND METHODS

PATIENTS
Bone marrow samples were obtained from 24 patients with newly diagnosed AML; all included in chemotherapy trials initiated by the French Multicenter Group, Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). All studies were approved by the GOELAMS Institutional Review Board, and signed informed consent was obtained in accordance with the Declaration of Helsinki.
CELLS CULTURES AND REAGENTS
Blast cells were isolated from bone marrow aspirates by Ficoll-Hypaque gradient density centrifugation as previously described 5 . Only samples with more than 80% of blast cells were used. Normal peripheral CD34 + cells were purified from 6 healthy donors after informed consent using MIDI-MACS immunoaffinity columns (Miltenyi Biotech, Bergish Badgach, Germany) (>95% CD34 + cells). LY294002 was purchased from Sigma (Saint Louis, MO), RAD001 was provided by Novartis (Basel, Switzerland) and 4EGI-1 was kindly given by Dr Gerhard Wagner (Harvard Medical School, Boston, MA).
COLONY ASSAYS
Clonogenic assays of normal CD34+ hematopoietic progenitors
Normal CD34 + cells were plated in duplicate (5.10 4 /ml) in 1 mL H4100 medium (StemCell Technologies, Vancouver, BC) with 10% FCS, 0,8% Bovine Serum Albumine, 1,7mmol/l glutamine, 10 -4 mol/l β-mercaptoethanol), 1UI/ml erythropoietin, 2,5ng/ml GM-CSF, 1000UI/ml IL-3, 10ng/ml SCF, 20ng/ml IL-6, and 2,5ng/ml G-CSF. The erythroid (BFU-E), granulo-macrophagic (CFU-GM), and granulo-erythroid-megakaryocytic-monocytic (CFU-GEMM) colony forming units were counted under an inverted microscope 28 .
Colony Forming Unit-Leukemia (CFU-L) assays
CFU-L assays were performed as previously reported 13, 15 . Blast cells were cultured in duplicate in H4230 medium (StemCell Technologies) with 10% 5637 conditioned medium.
At day 7, CFU-L (colony of more than 20 cells), were scored under inverted microscope. Sigma. Proteins were visualized using a secondary antibody conjugated to HRP, and chemiluminescence detection (Enhanced chemiluminescence, GE Healthcare). The images were captured using a CCD camera (LAS3000 from FujiFilm) and quantified using
Multigauge software from Fujifilm.
REAL TIME QUANTITATIVE PCR
Reverse transcription and real-time PCR were performed as previously described 29 . Primers for human c-Myc were: forward: GGAACTCTTGTGCGTAAGGA; reverse:
CAAGACTCAGCCAAGGTTGTG. Primers for human β-actin were: forward:
TCCCTGGAGAAGAGCTACGA; reverse: AGCACTGTGTTGGCGTACAG.
STATISTICAL ANALYSIS
Statistical significance of differences observed between experimental groups was determined using Student's t-test. In each case using primary AML cells, independent experiments means: i) that the experiments were performed in different days and ii) that cells from different patients were used.
RESULTS
4EGI-1 inhibits the clonogenic growth of AML progenitors and induces their apoptosis
with minimal impairment of normal hematopoiesis.
The 4EGI-1 compound has recently been identified through a high-throughput screening assay for small-molecule inhibitors of the eIF4E/eIF4G interaction 27 . Thus, 4EGI-1 behaves as a cell permeable 4E-BP1 mimetic that inhibits cap-dependent mRNA translation.
This compound exhibits growth inhibitory activity against multiple cancer cell types at concentrations ranging from 50 to 200 µmol/l 27 .
We Hence, 4EGI-1 appeared to have a marked differential effect on transformed versus non-transformed hematopoietic cells, which sharply contrasted with the effects of rapamycin on primary AML cells. As previously reported by others using rapamycin 4 , we confirmed that in AML RAD001 reduced cell proliferation and CFU-L formation but did not induce apoptosis ( Figures S1A-S1C ). Since translation appeared essential for AML cells survival and as mTORC1 has been shown to control the initiation step of translation through the phosphorylation of 4E-BP1 in most models, we investigated whether mTORC1 signaling could be deregulated in AML.
The phosphorylation of 4E-BP1 is independent of the activity of mTORC1 in AML blast cells.
We assessed the phosphorylation status of the two main mTORC1 substrates, P70S6K
and 4E-BP1 in 24 AML samples. As shown for sample #1, P70S6K T 389 and 4E-BP1 S 65 phosphorylation levels were maintained after 12 hours of serum and cytokine starvation ( Figure 3A ). We evaluated P70S6K and 4E-BP1 phosphorylation status after 4 hours of starvation in all samples, as reported for PI3K/Akt constitutive activity 5, 29 . representative AML samples is provided in Figure 3A .
We next tested the effects of RAD001 on mTORC1 signaling in AML. First, AML blast cells were cultured in starvation conditions to study their intrinsic signaling capacities.
In all samples analyzed, RAD001 was found to fully inhibit the phosphorylation of P70S6K on T 389 , but did not decrease 4E-BP1 S 65 phosphorylation. A representative western blot is shown in Figure 3B (Sample #28) and quantification of the immunoblotting signals from 8 AML samples is provided in Figure 3C . was found when increasing the concentrations of RAD001 up to 100nmol/l ( Figure S2B ) In all AML samples tested, LY294002 suppressed both P70S6K and 4E-BP1 phosphorylation.
To confirm that the disruption of the mTORC1 complex (defined by the raptor/mTOR association 30 ) did not inhibit 4E-BP1 phosphorylation, we verified that RAD001 induced a dissociation of raptor from mTOR in AML cells. Indeed, we confirmed that mTOR coprecipitated with raptor in control cells but not in RAD001-treated cells while at the same time RAD001 fully inhibited P70S6K T 389 phosphorylation but did not decrease 4E-BP1 phosphorylation on S 65 ( Figure 3D ). Lastly, we performed raptor siRNA experiments to specifically disrupt mTORC1 activity. Primary AML cells transfected with raptor siRNA
showed an 80% decrease of raptor expression that paralleled the decrease of P70S6K T 389 phosphorylation (p<0.001). Conversely, this siRNA-induced raptor knockdown had no effect upon 4E-BP1 S 65 phosphorylation ( Figure 3E ).
These data showed that the specific blockage of mTORC1 activity in AML cells resulted in the inhibition of P70S6K phosphorylation but not of 4E-BP1 phosphorylation, thereby demonstrating that 4E-BP1 phosphorylation escaped mTORC1 control in AML.
EIF4F complex formation is abrogated in AML by 4EGI-1 but not by RAD001.
Translation of mRNA is tightly regulated at the initiation level through the assembly of eIF4F complexes 18 . We compared the effects of three potential translation inhibitors on eIF4F assembly by pull-down assays using 7 m-GTP-Sepharose beads that mimic the cap structure of mRNA 8 .
Cells were separately treated with LY294002, RAD001 and the translation inhibitor 4EGI-1. Figure 4A illustrates the results of these experiments in primary AML samples and in the MOLM-14 leukemic cell line. Quantification analysis was done for 6 independent analyses of primary AML samples ( Figure 4B ). Western blots using whole cell lysates showed that these inhibitors did not significantly reduce the cellular amounts of eIF4G, eIF4E
or 4E-BP1 except for AML cells incubated with 100µmol/l 4EGI-1 ( Figure 4A ), which was most likely due to the high level of apoptosis induced by this concentration of 4EGI-1 in AML cells (Figure 2 ). Incubation with LY294002 increased the 4E-BP1 levels and decreased the amounts of eIF4G bound to eIF4E, indicating a major inhibition of eIF4F complex assembly and 4EGI-1 fully inhibited the interaction between eIF4E and eIF4G. Conversely, exposure to RAD001 did not modify the amounts of eIF4G or 4E-BP1 bound to eIF4E
( Figures 4A/B) .
We conclude from these analyses that mTORC1 inhibition by RAD001 failed to inhibit eIF4F assembly.
For 
Oncogenic protein accumulation is abrogated by 4EGI-1 but not by RAD001 in AML cells.
To further study the impact of RAD001, LY294002 Figure 6A ). Moreover, the expression of proteins widely implicated in oncogenic processes and regulated at the translation initiation level, c-Myc, Cyclin D1 and Bcl-xL, was examined by western blotting in five AML samples cultured during 24h in 10% FCS media without or with 10nmol/l RAD001, 50 or 100µmol/l 4EGI-1. In all samples treated with RAD001, the amounts of these proteins were identical to the control condition. Conversely, 4EGI-1 dramatically reduced the accumulation of these oncogenic proteins (from 60 to 80%, p<0.001). Analysis of a representative sample (#2) and data quantification from 5 independent experiments are shown in Figure 6B . Therefore, we confirmed that 4EGI-1 but not RAD001
induced a major decrease in the translation of malignancy-related mRNAs in primary AML cells.
Altogether, our results show that the control of protein synthesis escaped mTORC1 control in AML. Nevertheless, results of experiments using LY294002 suggested that another kinase may regulate 4E-BP1 phosphorylation and protein synthesis. LY294002 is a broadspectrum inhibitor of class 1A PI3K. However, specifically blocking PI3K activity in AML cells using the p110δ inhibitor IC87114 did not inhibit 4E-BP1 phosphorylation, even in the presence of rapamycin ( Figure S3 ). LY294002 has also been reported to inhibit the activity of Pim kinases 31 . Interestingly, the Pim-2 kinase has been implicated in the control of 4E-BP1 phosphorylation 32, 33 . We therefore tested whether this kinase could be involved in 4E-BP1 phosphorylation and in the control of protein synthesis in AML cells. Figure 7A . In contrast, Pim-2 was barely detectable in normal CD34+ hematopoietic progenitors ( Figure 7A ).
As no specific cell permeable Pim-2 inhibitor is available yet, we achieved Pim-2 knockdown in six AML samples by siRNA and a clear decrease of 4E-BP1 S 65 phosphorylation paralleled the reduction of Pim-2 expression in the transfected cells ( Figure   7B ). Interestingly, Pim-2 knockdown also inhibited the phosphorylation of the pro-apoptotic protein BAD on S 118 ( Figure 7B ). Indeed, BAD S 118 (equivalent to S 112 in murine BAD) has been previously described as a direct substrate for Pim-2 35 . Interestingly, P70S6K T 
DISCUSSION
A prevailing model suggests that cancers that are dependent upon the activation of the Akt oncoprotein rely on the subsequent activation of mTORC1 to drive tumorigenesis, leading to the clinical development of rapamycin as a cancer drug 36 . However in AML, despite a frequent activation of mTORC1, rapamycin is essentially cytostatic and only enhances chemotherapy-induced apoptosis 4 , which markedly contrasts with the expected effects of mTORC1 inhibition since this complex is thought to control cap-dependent mRNA translation which is essential for cancer cells.
In this report, we established that the control of translation is of major importance for AML biology using the 4EGI-1 compound, which pharmacologically mimics the 4E-BP1 translation repressor activity 27 . When used for the first time in primary AML samples, 4EGI-1 markedly impaired the clonogenic growth of leukemic progenitors and massively induced apoptosis of blast cells and interestingly, these effects occurred with a minimal degree of toxicity against normal hematopoietic processes.
Since the concentrations of 4EGI-1 required to inhibit protein synthesis and to induce apoptosis are rather high (see ref 27 and our present results), we sought for off-target effects of this compound. As shown in Figure S3 , 4EGI-1 neither decreased Akt, Erk and mTORC1 activity nor induced caspase-3 cleavage during the first 8 hours of cell incubation although protein synthesis was strongly inhibited from 2h hours of exposure to 4EGI-1 ( Figure 6A ), suggesting that apoptosis observed in AML cells after 24 hours of incubation is the direct consequence of translation inhibition rather than off-target effects of 4EGI-1.
As the anti-leukemic activity of 4EGI-1 was dramatically superior to the effects of RAD001 in AML 4, 13 , we studied mTORC1 signaling in primary AML samples. We examined 4E-BP1 phosphorylation and particularly focused on its S 65 residue, which is phosphorylated in last and is absolutely required to abrogate the repressor activity of 4E-BP1 against eIF4F Another recent work by Thoreen et al. shows that in MEF cells, 4E-BP1 phosphorylation is also rapamycin-resistant 40 . However in both cases, 4E-BP1 phosphorylation requires raptor and not Pim-2, which is different from the mechanisms we observed in AML cells.
Nevertheless, the regulation of 4E-BP1 phosphorylation is complex and we do not rule out that a raptor-independent activity of mTOR may be required for 4E-BP1 T 37/46 priming phosphorylation events 21, 22, 23 . Interestingly, we observed that these priming events were abolished by PI-103, a dual PI3K and mTOR catalytic inhibitor 13, 15 and by mTOR siRNA (data not shown). This suggests that mTOR, in a rapamycin-insensitive and raptorindependent complex could be responsible for the priming phosphorylation of 4E-BP1.
We further demonstrated the absence of control of mRNA translation by mTORC1 by . Interestingly, Pim-2 complements wtFLT3 to transform 32D cells suggesting that it is an essential effector of myeloid leukemogenesis 46, 47 . Pim kinases have also been implicated in AML cells survival and targeted therapy suppresses in vitro growth of leukemic cells 48 .
When tested in 24 AML samples, Pim-2 was detected in 23 cases, whereas its expression was markedly low in normal CD34+ cells. Interestingly, the Pim-1 protein was seldom found expressed in AML cells (data not shown), which illustrated the non-redundant functions of these kinases 33 . In primary AML cells, the siRNA-mediated decrease of 50 .
In summary, our results demonstrate that cap-dependent translation leading to the synthesis of highly oncogenic proteins is deregulated in AML. This process escapes mTORC1
and is controlled in part by a Pim-2/4E-BP1 axis that explains both the absence of translation inhibition by rapamycin and its weak clinical efficacy in AML (see Figure S6 for a schematic overview). We strongly suggest that direct targeting of the translation initiating complex using For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
